pyrazines has been researched along with Fatty Liver in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.09) | 29.6817 |
| 2010's | 18 (81.82) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y; Sun, X; Wang, X; Wang, Y; Xiang, Y; Xiao, F | 1 |
| Lin, J; Wang, SY | 1 |
| Kim, W; Kim, YJ | 1 |
| Konishi, H; Kyohara, M; Okuyama, T; Shirakawa, J; Tajima, K; Terauchi, Y; Togashi, Y; Yamazaki, S | 1 |
| Akaslan, SB; Arslan, M; Cakir, N; Degertekin, CK; Toruner, FB; Yilmaz, G | 1 |
| Chan, JY; Ho, DV; Lee, CS | 1 |
| Abdennebi, HB; Bardag-Gorce, F; Bejaoui, M; Carbonell, T; Folch-Puy, E; Oliva, J; Pantazi, E; Rimola, A; Roselló-Catafau, J; Zaouali, MA | 1 |
| Anand, S; Bhatia, T; Olaywi, M; Singhal, S | 1 |
| Anderson, CD; Busch, RA; Chapman, WC; Dines, JN; Gunter, KL; Jia, J; Knolhoff, BL; Mohanakumar, T; Ramachandran, S; Sarma, NJ; Tiriveedhi, V; Upadhya, GA | 1 |
| Choi, YK; Jang, BK; Jung, GS; Jung, YA; Kim, HS; Kim, JG; Kim, MK; Lee, IK; Park, KG; Seo, HY | 1 |
| Chen, L; Chen, Q; Jin, H; Lu, C; Lu, Y; Shao, J; Wu, L; Xu, W; Zhang, F; Zheng, S | 1 |
| Chang, MS; Cho, JY; Kim, BG; Kim, H; Kim, JH; Kim, SG; Kim, W; Kim, YJ; Lee, CK; Lee, J; Lee, JH; Lee, JS; Yeon, JE; Yi, S | 1 |
| Bae, EJ; Hwahng, SH; Ki, SH; Kim, HE; Kim, SG | 1 |
| Brooks, JS; Brooks, SC; Kim, SG; Lee, MG; Lee, WH | 1 |
| Cross, LB; Foard, J; Gross, BN; Wood, Y | 1 |
| Borelli, MI; Del Zotto, H; Flores, LE; Francini, F; Gagliardino, JJ; Madrid, VG; Maiztegui, B; Massa, ML; Raschia, MA; Rebolledo, OR | 1 |
| Chapman, WC; Csontos, K; Glasgow, SC; Jia, J; Liaw, JM; Liu, W; Mohanakumar, T; Ramachandran, S; Upadhya, GA | 1 |
| Celikel, CA; Deyneli, O; Duman, DG; Kalayci, C; Yilmaz, Y; Yonal, O | 1 |
| Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H | 1 |
| Eom, JS; Kim, SG; Kim, TH; Lee, CG; Lee, YS; Yang, YM | 1 |
| Bardag-Gorce, F; Bejaoui, M; Ben Abdennebi, H; Carbonell, T; Oliva, J; Pantazi, E; Rimola, A; Roselló-Catafau, J; Zaouali, MA | 1 |
| DUSI, U; GRECO, S; MENOZZI, V | 1 |
2 review(s) available for pyrazines and Fatty Liver
| Article | Year |
|---|---|
Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review.
Topics: Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fatty Liver; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Liver; Non-alcoholic Fatty Liver Disease; Peptides; Pyrazines; Sitagliptin Phosphate; Transaminases; Treatment Outcome; Triazoles; Venoms | 2013 |
Therapeutic potential of dithiolethiones for hepatic diseases.
Topics: Animals; CCAAT-Enhancer-Binding Protein-beta; Fatty Liver; Glutathione Transferase; Humans; Inactivation, Metabolic; Insulin Resistance; Liver; Liver Cirrhosis; Liver Diseases; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Protein Kinases; Pyrazines; Receptors, Aryl Hydrocarbon; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Thiones; Thiophenes; TOR Serine-Threonine Kinases | 2009 |
1 trial(s) available for pyrazines and Fatty Liver
| Article | Year |
|---|---|
Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.
Topics: Adult; Animals; Double-Blind Method; Fatty Liver; Female; Humans; Liver X Receptors; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Mice; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes; Treatment Outcome; Ultrasonography | 2017 |
19 other study(ies) available for pyrazines and Fatty Liver
| Article | Year |
|---|---|
2,3,5,6-Tetramethylpyrazine improves diet-induced whole-body insulin resistance via suppressing white adipose tissue lipolysis in mice.
Topics: Adipose Tissue, White; Animals; Diet, High-Fat; Fatty Liver; Glucose; Insulin Resistance; Lipolysis; Male; Mice; Muscle, Skeletal; Pyrazines | 2020 |
Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed.
Topics: Fatty Liver; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes | 2017 |
Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed-authors' reply.
Topics: Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes | 2017 |
Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906.
Topics: Animals; Cell Proliferation; Dietary Supplements; Energy Metabolism; Fatty Liver; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Imidazoles; Insulin-Secreting Cells; Leptin; Lipodystrophy; Mice; Pyrazines; Safety-Based Drug Withdrawals; Time Factors; Tomography, X-Ray Computed | 2017 |
Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
Topics: Alanine Transaminase; Animals; Blood Glucose; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Female; Insulin; Insulin Resistance; Liver; Non-alcoholic Fatty Liver Disease; Obesity; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles; Triglycerides | 2013 |
Nuclear factor-erythroid 2-related factor 1 regulates expression of proteasome genes in hepatocytes and protects against endoplasmic reticulum stress and steatosis in mice.
Topics: Animals; Boronic Acids; Bortezomib; Endoplasmic Reticulum Stress; Fatty Liver; Gene Expression; Gene Expression Regulation, Enzymologic; Hepatocytes; Liver; Mice; Mice, Knockout; NF-E2-Related Factor 1; Proteasome Endopeptidase Complex; Pyrazines | 2013 |
Bortezomib enhances fatty liver preservation in Institut George Lopez-1 solution through adenosine monophosphate activated protein kinase and Akt/mTOR pathways.
Topics: AMP-Activated Protein Kinases; Animals; Boronic Acids; Bortezomib; Fatty Liver; Liver; Organ Preservation; Organ Preservation Solutions; Proto-Oncogene Proteins c-akt; Pyrazines; Rats; Rats, Zucker; Reperfusion Injury; Solutions; TOR Serine-Threonine Kinases | 2014 |
Protective role of bortezomib in steatotic liver ischemia/reperfusion injury through abrogation of MMP activation and YKL-40 expression.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Chitinase-3-Like Protein 1; Enzyme Activation; Extracellular Matrix Proteins; Fatty Liver; Gene Expression Regulation; Glycoproteins; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrazines; Rats; Rats, Zucker; Reperfusion Injury | 2014 |
Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis.
Topics: Animals; Biomarkers; Blotting, Western; Choline Deficiency; Diet; Dipeptidyl-Peptidase IV Inhibitors; Endoplasmic Reticulum Stress; Fatty Liver; Immunoenzyme Techniques; Inflammation; Lipid Peroxidation; Liver Cirrhosis; Male; Methionine; Mice; Mice, Inbred C57BL; NF-kappa B; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sitagliptin Phosphate; Triazoles; Triglycerides | 2014 |
Ligustrazine prevents alcohol-induced liver injury by attenuating hepatic steatosis and oxidative stress.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Fatty Liver; Liver Diseases, Alcoholic; Male; Oxidative Stress; Pyrazines; Rats; Rats, Sprague-Dawley | 2015 |
Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones.
Topics: Animals; Cyclic AMP-Dependent Protein Kinases; DNA-Binding Proteins; Fatty Liver; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Orphan Nuclear Receptors; Pyrazines; Receptors, Cytoplasmic and Nuclear; Ribosomal Protein S6 Kinases, 70-kDa; Sterol Regulatory Element Binding Protein 1; Thiones; Thiophenes; Transcriptional Activation | 2009 |
Elevated hepatic enzymes potentially associated with sitagliptin.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Humans; Liver; Liver Function Tests; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Diet; Dipeptidyl-Peptidase IV Inhibitors; Drinking; Drug Evaluation, Preclinical; Eating; Exenatide; Fatty Liver; Fructose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metabolic Syndrome; Peptides; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Ischemia-reperfusion injury in rat steatotic liver is dependent on NFκB P65 activation.
Topics: Animals; Boronic Acids; Bortezomib; Chemokine CXCL2; Disease Models, Animal; Fatty Liver; Humans; Inflammation Mediators; Interleukin-1beta; Liver; Proteasome Inhibitors; Pyrazines; Rats; Rats, Zucker; Reperfusion Injury; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2012 |
Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis.
Topics: Adult; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fatty Liver; Female; Hepatocytes; Humans; Male; Middle Aged; Pilot Projects; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
Topics: Adult; Alanine Transaminase; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Drug Evaluation; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Inflammation; Liraglutide; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Odds Ratio; Pioglitazone; Platelet Count; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2012 |
An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Antioxidants; Diet, High-Fat; Enzyme Activation; Fatty Liver; Hep G2 Cells; Humans; Lipid Metabolism; Lipogenesis; Liver; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Mitochondria; Orphan Nuclear Receptors; Oxidation-Reduction; Oxidative Stress; Pyrazines; Sterol Regulatory Element Binding Protein 1; Thiones; Thiophenes | 2013 |
Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury.
Topics: Adiponectin; Animals; Boronic Acids; Bortezomib; Cold Ischemia; Cysteine Proteinase Inhibitors; Cytoprotection; Fatty Liver; Interleukin-1; Leupeptins; Liver Transplantation; Mitochondria, Liver; Organ Preservation; Organ Preservation Solutions; Oxidative Stress; Proteasome Inhibitors; Pyrazines; Rats; Rats, Zucker; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2013 |
[PRELIMINARY FUNCTIONAL AND MORPHOLOGICAL HEPATIC FINDINGS IN PATIENTS TREATED WITH MORPHAZINAMIDE].
Topics: Antitubercular Agents; Fatty Liver; Humans; Liver Function Tests; Pyrazinamide; Pyrazines; Silicotuberculosis; Toxicology; Tuberculosis; Tuberculosis, Pulmonary | 1963 |